L1 Capital Global, Inc. recently announced the acquisition of new stake in Palisade Bio Inc (NASDAQ:PALI). This fresh investment now brings its stake to 5.91% valued currently at $0.32 million. In addition, The Vanguard Group, Inc. raised its holdings by 32485.0 to 68054.0 shares.
Currently, there are 9.27M common shares owned by the public and among those 8.50M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 21 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 12 of these insider trades were purchases, accounting for 75,121 shares. Insider sales of the common stock occurred on 9 occasions, with total insider shares sold totaling 7,303 shares.
The top 3 mutual fund holders in Palisade Bio Inc are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Series Total Market Inde. Vanguard Extended Market Index Fu owns 68054.0 shares of the company’s stock, all valued at over $40152.0. Fidelity Series Total Market Inde now owns shares totaling to 0.02% of the shares outstanding.
The company’s stock has a 5-day price change of 81.13% and 65.06% over the past three months. PALI shares are trading 62.71% year to date (YTD), with the 12-month market performance down to -56.76% lower. It has a 12-month low price of $0.50 and touched a high of $3.65 over the same period. PALI has an average intraday trading volume of 292.22K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 77.21%, 67.73%, and -10.21% respectively.
Institutional ownership of Palisade Bio Inc (NASDAQ: PALI) shares accounts for 7.48% of the company’s 9.27M shares outstanding. Mutual fund holders own 1.11%, while other institutional holders and individual stakeholders account for 6.41% and 0.97% respectively.
It has a market capitalization of $8.90M and a beta (3y monthly) value of 1.41. The earnings-per-share (ttm) stands at -$2.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.66% over the week and 8.35% over the month.
Analysts forecast that Palisade Bio Inc (PALI) will achieve an EPS of -$0.34 for the current quarter, -$0.32 for the next quarter and -$0.95 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.36 while analysts give the company a high EPS estimate of -$0.33. Comparatively, EPS for the current quarter was $6.47 a year ago. Earnings per share for the fiscal year are expected to increase by 88.65%, and 49.06% over the next financial year.
